Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | BRS3 | P32247 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | IL2 | P60568 | 1/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555073 | 0.88 | NAMPT (0.48) | NAMPTCYP17A1RAB9AMETAP1ATR | |
| SCHEMBL18522430 | 0.87 | NAMPT (0.50) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL3666785 | 0.84 | NAMPT (0.48) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL15432258 | 0.83 | HPGD (0.49) | RAB9AIL2 | |
| SCHEMBL16307603 | 0.83 | CYP17A1 (0.55) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL4037373 | 0.83 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL15039524 | 0.83 | CYP17A1 (0.55) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL741240 | 0.83 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL4827917 | 0.83 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL5746021 | 0.83 | NAMPT (0.47) | NAMPTCYP17A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-11 | — | — | US | disclosed |
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2024-12-24 | — | — | US | disclosed |
| US-20230374006-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-23 | — | — | US | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| WO-2005032481-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2004104001-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| EP-0997465-B1 | Azaindole derivatives and their use as antithrombotic agents | LILLY CO ELI (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6380230-B1 | FOR THERAPY OF DYSKINESIA, OBESITY, IRRITABLE BOWEL SYNDROME, DISEASES WHOSE TREATMENT REQUIRES STIMULATION OF THE CHOLECYSTOKININ CCK-A RECEPTORS | SANOFI-SYNTHELABO (FR) | 2002-04-30 | — | — | US | disclosed |
| US-6359136-B1 | AZAINDOLE COMPOUND | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | disclosed |
| US-6265416-B1 | ANTICOAGULANTS | ELI LILLY AND COMPANY | 2001-07-24 | — | — | US | disclosed |
| EP-1017693-A1 | CARBOXAMIDOTHIAZOLE DERIVATIVES, PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2000-07-12 | — | — | EP | disclosed |
| EP-0997465-A1 | Azaindole derivatives and their use as antithrombotic agents | ELI LILLY AND COMPANY (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999015525-A1 | CARBOXAMIDOTHIAZOLE DERIVATIVES, PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 1999-04-01 | — | — | WO | disclosed |
| US-5681959-A | DEPROTONATION OF A 2-AMINO-3-ALKYLPYRIDINE WITH AN ALKYLLITHIUM COMPOUND, THEN REACTION WITH AN AMIDE OR ESTER AND TREATMENT WITH A CONCENTRATED ACID FOR CYCLIZATION | MERCK, SHARP & DOHME LTD. (GB) | 1997-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374006-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | MAPT, APP, SLCO1B3 | NAMPT 3012/4885CYP17A1 751/4885RAB9A 603/4885 |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | NAMPT 3268/4885CYP17A1 4410/4885RAB9A 2816/4885 |
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | NAMPT 3268/4885CYP17A1 4410/4885RAB9A 2816/4885 |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | NAMPT 3268/4885CYP17A1 4410/4885RAB9A 2816/4885 |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | NAMPT 1345/4885CYP17A1 4412/4885RAB9A 1713/4885 |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | NAMPT 3268/4885CYP17A1 4410/4885RAB9A 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.